Matching articles for "aflibercept"
A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • May 2, 2022; (Issue 1649)
The FDA has approved Susvimo (Genentech), a
refillable permanent ocular implant containing the
vascular endothelial growth factor (VEGF) inhibitor
ranibizumab, for treatment of neovascular (wet)...
The FDA has approved Susvimo (Genentech), a
refillable permanent ocular implant containing the
vascular endothelial growth factor (VEGF) inhibitor
ranibizumab, for treatment of neovascular (wet) age-related
macular degeneration (nAMD) in patients who
have previously responded to at least two intravitreal
injections of a VEGF inhibitor. Ranibizumab intravitreal
injection (Lucentis) has been available since 2006 for
monthly treatment of nAMD. The FDA has approved
ranibizumab-nuna (Byooviz), a biosimilar of Lucentis
and the first ophthalmologic biosimilar; it will be
available in June 2022.
Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema
The Medical Letter on Drugs and Therapeutics • March 21, 2022; (Issue 1646)
Faricimab-svoa (Vabysmo – Genentech), an inhibitor
of both vascular endothelial growth factor (VEGF)
and angiopoietin-2 (Ang-2), has been approved by
the FDA for intravitreal treatment of...
Faricimab-svoa (Vabysmo – Genentech), an inhibitor
of both vascular endothelial growth factor (VEGF)
and angiopoietin-2 (Ang-2), has been approved by
the FDA for intravitreal treatment of neovascular
(wet) age-related macular degeneration (nAMD) and
diabetic macular edema (DME). It is the first drug to
become available in the US that targets two pathways
involved in maintaining vascular homeostasis.
Several VEGF inhibitors are available for treatment of
nAMD and DME (see Table 2).
Brolucizumab (Beovu) for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • February 10, 2020; (Issue 1591)
Brolucizumab-dbll (Beovu — Novartis), a vascular
endothelial growth factor (VEGF) inhibitor, has been
approved by the FDA as an intravitreal injection for
treatment of neovascular (wet) age-related...
Brolucizumab-dbll (Beovu — Novartis), a vascular
endothelial growth factor (VEGF) inhibitor, has been
approved by the FDA as an intravitreal injection for
treatment of neovascular (wet) age-related macular
degeneration (AMD). It is the fourth VEGF inhibitor to
be approved in the US for this indication; bevacizumab
(Avastin, and others), a VEGF inhibitor FDA-approved
for treatment of breast cancer and other malignancies,
has been used off-label for this indication for years.
Drugs for Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • December 2, 2019; (Issue 1586)
This issue includes reviews of drugs for glaucoma,
age-related macular degeneration (AMD), bacterial
conjunctivitis, and dry eye disease. Allergic conjunctivitis
is reviewed in a separate...
This issue includes reviews of drugs for glaucoma,
age-related macular degeneration (AMD), bacterial
conjunctivitis, and dry eye disease. Allergic conjunctivitis
is reviewed in a separate issue.
VEGF Inhibitors for AMD and Diabetic Macular Edema
The Medical Letter on Drugs and Therapeutics • March 16, 2015; (Issue 1464)
Vascular endothelial growth factor (VEGF) is a principal
mediator of neovascularization in wet age-related
macular degeneration (AMD) and diabetic macular
edema. It induces angiogenesis and increases...
Vascular endothelial growth factor (VEGF) is a principal
mediator of neovascularization in wet age-related
macular degeneration (AMD) and diabetic macular
edema. It induces angiogenesis and increases vascular
permeability and inflammation. VEGF inhibitors reduce
leakage from blood vessels, prevent proliferation of
new abnormal vessels, decrease swelling of the retina,
and improve visual acuity in patients with neovascular
(wet) AMD and diabetic macular edema. These drugs
are given as periodic intravitreal injections with topical
anesthesia.
Ziv-Aflibercept (Zaltrap) for Metastatic Colorectal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • April 29, 2013; (Issue 1415)
Ziv-aflibercept (Zaltrap – Sanofi/Regeneron), a vascular
endothelial growth factor (VEGF) inhibitor, has
been approved by the FDA for use in combination with
5-fluorouracil, leucovorin and irinotecan...
Ziv-aflibercept (Zaltrap – Sanofi/Regeneron), a vascular
endothelial growth factor (VEGF) inhibitor, has
been approved by the FDA for use in combination with
5-fluorouracil, leucovorin and irinotecan (FOLFIRI) for
treatment of metastatic colorectal cancer that is resistant
to or has progressed following an oxaliplatin-containing
regimen. It is the same drug as aflibercept,
which was approved last year as an intravitreal injection
(Eylea) for treatment of neovascular (wet) agerelated
macular degeneration (AMD). Ziv-aflibercept
is the second VEGF inhibitor approved for treatment of
metastatic colorectal cancer; bevacizumab (Avastin),
given in addition to chemotherapy, is a standard firstand
second-line therapy.
Aflibercept (Eylea) for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • February 6, 2012; (Issue 1383)
The FDA has approved aflibercept (a flib’ er sept;
Eylea – Regeneron) for treatment of neovascular (wet)
age-related macular degeneration...
The FDA has approved aflibercept (a flib’ er sept;
Eylea – Regeneron) for treatment of neovascular (wet)
age-related macular degeneration (AMD).